WO2002058732A3 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications - Google Patents
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Download PDFInfo
- Publication number
- WO2002058732A3 WO2002058732A3 PCT/US2002/002009 US0202009W WO02058732A3 WO 2002058732 A3 WO2002058732 A3 WO 2002058732A3 US 0202009 W US0202009 W US 0202009W WO 02058732 A3 WO02058732 A3 WO 02058732A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activated receptor
- peroxisome proliferator
- activator
- absorption inhibitor
- combinations
- Prior art date
Links
- 0 *C(C=CC12)=CC=C1C2(*1c(cc2)ccc2N)[C@@](CCC2(CC2)c(cc2)ccc2N)C1=O Chemical compound *C(C=CC12)=CC=C1C2(*1c(cc2)ccc2N)[C@@](CCC2(CC2)c(cc2)ccc2N)C1=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037009749A KR100596257B1 (en) | 2001-01-26 | 2002-01-25 | A composition comprising sterol absorption inhibitor, and a composition and a therapeutic combinations comprising peroxisome proliferator-activated receptorPPAR activator and sterol absorption inhibitor |
DE60216890T DE60216890T2 (en) | 2001-01-26 | 2002-01-25 | COMBINATIONS OF A STARTER ABSORPTION HEMMER AND A PPAR ACTIVATOR FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS |
BR0206654-8A BR0206654A (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferation-activated receptor (s) activator (s) and sterol absorption inhibitor (s) and treatments for vascular indications |
YUP-586/03A RS51449B (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
JP2002559066A JP4777602B2 (en) | 2001-01-26 | 2002-01-25 | Combination of peroxisome proliferator activated receptor (PPAR) activator and sterol absorption inhibitor and treatment of vascular symptoms |
HU0303915A HUP0303915A3 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
MEP-278/08A MEP27808A (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
HU1500186A HU230253B1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and their use in the treatment of vascular indications |
CA002434682A CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
IL15644502A IL156445A0 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
DK04000161T DK1413331T3 (en) | 2001-01-26 | 2002-01-25 | Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate and the sterol absorption inhibitor ezetimibe for vascular indications |
EP02714773A EP1353696B1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
AU2002247019A AU2002247019C1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
MXPA03006725A MXPA03006725A (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications. |
SK50001-2012A SK288217B6 (en) | 2001-01-26 | 2002-01-25 | Composition, therapeutic combination, pharmaceutical preparation and use thereof |
DK02714773T DK1353696T3 (en) | 2001-01-26 | 2002-01-25 | Combinations of Peroxisome Proliferator Activated Receptor (PPAR) Activator (s) and Sterol Absorption Inhibitor (s) and Treatments for Vascular Indications |
SI200230471T SI1353696T1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
SK948-2003A SK287988B6 (en) | 2001-01-26 | 2002-01-25 | Composition, oral dosage form and use thereof |
NZ525921A NZ525921A (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
IL156445A IL156445A (en) | 2001-01-26 | 2003-06-15 | Composition of sterol absorption inhibitor or therapeutic combination thereof with cholesterol biosynthesis inhibitor, which may further comprise peroxisome proliferator activated receptor (ppar) activator |
ZA2003/05693A ZA200305693B (en) | 2001-01-26 | 2003-07-23 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
NO20033355A NO331512B1 (en) | 2001-01-26 | 2003-07-25 | Composition comprising sterol absorption inhibitor, oral dosage form comprising the composition and use of the composition for the preparation of a medicament for co-administration with activator (s) of peroxisome proliferator-activated receptor (PPAR) for the treatment and / or prevention of vascular indications |
HK03109220A HK1056696A1 (en) | 2001-01-26 | 2003-12-18 | Combinations of peroxisome proliferator-activated receptor (ppar) activator (S) and sterol absorption inhibitor (S) and treatments for vascular indications |
CL200401174A CL2004001174A1 (en) | 2001-01-26 | 2004-05-20 | PHARMACEUTICAL COMPOSITION INCLUDING: 1- (4-FLUOROPHENYL) -3 (R) - [3- (4-FLUOROPHENYL) -3 (S) -HYDROXIPROPIL] -4 (S) - (4-HYDROXIFENYL) -2-ACETIDINONE ( EZETIMIBA) AND EXCIPIENTS; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, DAY |
IL191417A IL191417A (en) | 2001-01-26 | 2008-05-13 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26439601P | 2001-01-26 | 2001-01-26 | |
US60/264,396 | 2001-01-26 | ||
US32383901P | 2001-09-21 | 2001-09-21 | |
US60/323,839 | 2001-09-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002058732A2 WO2002058732A2 (en) | 2002-08-01 |
WO2002058732A3 true WO2002058732A3 (en) | 2003-07-03 |
WO2002058732B1 WO2002058732B1 (en) | 2003-09-12 |
Family
ID=26950511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/002009 WO2002058732A2 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Country Status (33)
Country | Link |
---|---|
US (5) | US20020151536A1 (en) |
EP (2) | EP1413331B1 (en) |
JP (4) | JP4777602B2 (en) |
KR (1) | KR100596257B1 (en) |
CN (1) | CN100509058C (en) |
AR (2) | AR033855A1 (en) |
AT (2) | ATE374641T1 (en) |
AU (1) | AU2002247019C1 (en) |
BR (1) | BR0206654A (en) |
CA (3) | CA2434682C (en) |
CL (1) | CL2004001174A1 (en) |
CY (2) | CY1108000T1 (en) |
CZ (2) | CZ301871B6 (en) |
DE (2) | DE60216890T2 (en) |
DK (2) | DK1353696T3 (en) |
EC (1) | ECSP11004702A (en) |
ES (2) | ES2290562T3 (en) |
HK (2) | HK1056696A1 (en) |
HU (2) | HU230253B1 (en) |
IL (3) | IL156445A0 (en) |
ME (1) | MEP27808A (en) |
MX (1) | MXPA03006725A (en) |
NO (1) | NO331512B1 (en) |
NZ (1) | NZ525921A (en) |
PL (1) | PL208110B1 (en) |
PT (2) | PT1353696E (en) |
RS (2) | RS20100015A (en) |
RU (1) | RU2356550C2 (en) |
SI (2) | SI1353696T1 (en) |
SK (2) | SK287988B6 (en) |
TW (1) | TWI337083B (en) |
WO (1) | WO2002058732A2 (en) |
ZA (1) | ZA200305693B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2434033A1 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA2434488A1 (en) * | 2001-01-26 | 2002-08-01 | Harry R. Davis | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
JP2005504091A (en) * | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | Treatment of xanthomas with azetidinone as a sterol absorption inhibitor |
CA2459926A1 (en) * | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
NZ569868A (en) * | 2002-09-27 | 2010-01-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
MXPA05006513A (en) * | 2002-12-16 | 2005-09-08 | Kissei Pharmaceutical | Solid drug for oral use. |
WO2004069193A2 (en) * | 2003-02-03 | 2004-08-19 | Thomas Jefferson University | Methods and compositions for inhibiting cholesterol uptake |
MXPA05009503A (en) | 2003-03-07 | 2005-10-18 | Schering Corp | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia. |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2005015434A (en) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | Serum cholesterol-lowering agent or prophylactic or therapeutic agent for atherosclerosis |
CA2544309A1 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US7390504B2 (en) * | 2003-11-07 | 2008-06-24 | Jj Pharma, Inc. | HDL-boosting combination therapy complexes |
SA04250427A (en) | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | Diphenylazetidone derivates |
CA2553769C (en) * | 2004-01-16 | 2011-01-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
US20070116645A1 (en) * | 2004-02-03 | 2007-05-24 | Steven Farber | Methods and compositions for inhibiting cholesterol uptake |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
CN1759834B (en) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
UY29607A1 (en) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EA200800356A1 (en) * | 2005-07-18 | 2008-10-30 | Релайэнт Фармасьютикалз, Инк. | TREATING CHOLESTEROL ABSORPTION WITH AZETIDINONE AND OMEGA-3 INHIBITOR WITH FATTY ACIDS AND THEIR COMBINED DRUG |
US7910698B2 (en) * | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
AR060623A1 (en) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
US20070299017A1 (en) * | 2006-06-23 | 2007-12-27 | Kanter Mitchell M | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
EP2431043A1 (en) * | 2007-05-23 | 2012-03-21 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption |
EP2965752A1 (en) | 2007-12-10 | 2016-01-13 | ratiopharm GmbH | Pharmaceutical formulation comprising ezetimibe |
EP2168573A1 (en) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
AU2010206549B2 (en) * | 2009-01-26 | 2016-08-25 | Dcb-Usa, Llc | Use of pterosin compounds for treating diabetes and obesity |
EP2229938B9 (en) | 2009-03-13 | 2012-04-25 | Sanovel Ilac Sanayi ve Ticaret A.S. | Ezetimibe compositions |
CA2757722C (en) | 2009-04-01 | 2018-05-22 | Matrix Laboratories Ltd. | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
TR200904500A2 (en) | 2009-06-10 | 2009-10-21 | Öner Levent | Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals. |
US9572798B2 (en) | 2012-09-27 | 2017-02-21 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
KR20150079373A (en) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin |
CN104337785A (en) * | 2014-11-04 | 2015-02-11 | 万全万特制药江苏有限公司 | Orally disintegrating tablet containing ezetimibe and preparation method of orally disintegrating tablet |
CN105213340A (en) * | 2015-10-29 | 2016-01-06 | 无锡福祈制药有限公司 | A kind of Ezetimibe sheet and preparation method thereof |
JP2017210455A (en) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | Ezetimibe-containing pharmaceutical composition |
CN106310173A (en) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | Multi-vitamin acidity alcohol containing peroxisome proliferator activated receptor and preparing method thereof |
EP3437636A1 (en) | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
CN109718215A (en) * | 2017-10-30 | 2019-05-07 | 海南皇隆制药股份有限公司 | A kind of Ezetimibe piece |
KR101983298B1 (en) * | 2018-06-11 | 2019-05-29 | 연세대학교 산학협력단 | Pharmaceutical coomposition for preventing or treating inflammasome mediated inflammatory disease |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1999008501A2 (en) * | 1998-04-23 | 1999-02-25 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
WO2002026729A2 (en) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
WO2002050068A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
WO2002050027A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
WO2002050060A1 (en) * | 2000-12-21 | 2002-06-27 | Avantis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
WO2002064094A2 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108097A (en) * | 1963-10-22 | Ehnojs | ||
US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
US1286A (en) * | 1839-08-13 | Richard else | ||
NL238796A (en) * | 1958-05-07 | |||
NL127065C (en) * | 1964-04-22 | |||
NL137318C (en) * | 1964-06-09 | |||
US3716583A (en) * | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (en) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarboxylic acid derivatives and processes for making the same |
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (en) * | 1977-09-19 | 1979-04-13 | Lafon Labor | NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS |
IT1157365B (en) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (en) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
US4614614A (en) * | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (en) * | 1984-03-30 | 1987-12-11 | Lafon Labor | GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION |
US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (en) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
EP0234484B1 (en) * | 1986-02-19 | 1993-10-20 | Sanraku Incorporated | Novel azetidinone derivatives |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (en) * | 1986-04-30 | 1989-01-20 | Rech Ind | NEW PROCESS FOR THE PREPARATION OF FIBRATES. |
DE3621861A1 (en) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES |
FR2602423B1 (en) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
ZA879415B (en) | 1986-12-15 | 1989-08-30 | Lilly Co Eli | Antibiotic a10255 complex and factors,microorganisms,process and production therefor |
JPS63156788A (en) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | Optically active azetidinones |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
DE3877406T2 (en) * | 1987-04-28 | 1993-06-09 | Fujisawa Astra Ltd | BENZOTHIAZOLINONE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION. |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
US5385885A (en) * | 1988-01-15 | 1995-01-31 | Gasic; Gregory P. | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide |
FR2627696B1 (en) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
DE3807895A1 (en) * | 1988-03-10 | 1989-09-21 | Knoll Ag | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
FR2634376B1 (en) * | 1988-07-21 | 1992-04-17 | Farmalyoc | NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
CA1340977C (en) * | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (en) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (en) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
US5021461A (en) * | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2640986B2 (en) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
SK7994A3 (en) | 1991-07-23 | 1994-07-06 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes of their preparation |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5412092A (en) * | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
PL312502A1 (en) * | 1993-07-09 | 1996-04-29 | Schering Corp | Method of manufacturing azetidinones |
ES2162867T3 (en) * | 1993-07-09 | 2002-01-16 | Scherer Corp R P | METHOD OF MANUFACTURE OF DOSAGE FORMS OF LIOFILIZED PHARMACOS. |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
FR2730231B1 (en) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
JP3144624B2 (en) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
FR2738817B1 (en) * | 1995-09-14 | 1997-10-17 | Adir | NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
JP2000508659A (en) * | 1996-04-17 | 2000-07-11 | メルク エンド カンパニー インコーポレーテッド | Combination therapy to reduce cardiovascular disease-related risks |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
TR199802424T2 (en) * | 1996-05-24 | 1999-03-22 | Schering Corporation | Anti-fungal compound with increased bioavailability. |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
WO1997047209A1 (en) * | 1996-06-12 | 1997-12-18 | Kyowa Hakko Kogyo Co., Ltd. | Lipid metabolism ameliorants |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
FR2761266B1 (en) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
ATE290375T1 (en) * | 1997-04-02 | 2005-03-15 | Brigham & Womens Hospital | USE OF AN AGENT FOR REDUCING THE RISK OF CARDIOVASCULAR DISEASES |
ES2125198B1 (en) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND AN ANTAGONIST OF THE CALCIUM CHANNELS, PROCEDURE FOR ITS PREPARATION AND USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
AR016827A1 (en) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
DE69823843T2 (en) * | 1997-09-09 | 2005-05-12 | Bristol-Myers Squibb Pharma Co. | BENZIMIDAZOLINONE, BENZOXAZOLINONE, BENZOPIPERAZINONE, INDANONE AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
AU3110999A (en) * | 1998-03-27 | 1999-10-18 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6174665B1 (en) * | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
AU1756201A (en) * | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US20020132855A1 (en) * | 2000-08-03 | 2002-09-19 | Nelson Edward B. | Use of acetaminophen to prevent and treat arteriosclerosis |
DE10042447A1 (en) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport |
CA2434033A1 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
EP1385548B1 (en) * | 2001-01-26 | 2007-05-23 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
EP1389114A2 (en) * | 2001-03-08 | 2004-02-18 | Merck & Co., Inc. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
US7348334B2 (en) * | 2001-04-09 | 2008-03-25 | Dr. Reddy's Laboratories Limited | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
AR038956A1 (en) * | 2001-05-25 | 2005-02-02 | Schering Corp | USE OF A COMPOUND REGULATING THE PRODUCTION OR LEVELS OF BETA AMILOID PEPTIDES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT ALZHEIMER'S DISEASE AND / OR TO REGULATE SUCH LEVELS OF BETA AMILOID PEPTIDES IN A SUBJECT |
-
2002
- 2002-01-25 US US10/057,323 patent/US20020151536A1/en not_active Abandoned
- 2002-01-25 PT PT02714773T patent/PT1353696E/en unknown
- 2002-01-25 AT AT04000161T patent/ATE374641T1/en active
- 2002-01-25 PT PT04000161T patent/PT1413331E/en unknown
- 2002-01-25 JP JP2002559066A patent/JP4777602B2/en not_active Expired - Lifetime
- 2002-01-25 TW TW091101264A patent/TWI337083B/en not_active IP Right Cessation
- 2002-01-25 CA CA002434682A patent/CA2434682C/en not_active Expired - Lifetime
- 2002-01-25 DK DK02714773T patent/DK1353696T3/en active
- 2002-01-25 SI SI200230471T patent/SI1353696T1/en unknown
- 2002-01-25 AT AT02714773T patent/ATE348649T1/en active
- 2002-01-25 CA CA002563051A patent/CA2563051A1/en not_active Abandoned
- 2002-01-25 WO PCT/US2002/002009 patent/WO2002058732A2/en active Application Filing
- 2002-01-25 PL PL368653A patent/PL208110B1/en unknown
- 2002-01-25 AU AU2002247019A patent/AU2002247019C1/en active Active
- 2002-01-25 BR BR0206654-8A patent/BR0206654A/en not_active Application Discontinuation
- 2002-01-25 CA CA2562982A patent/CA2562982C/en not_active Expired - Fee Related
- 2002-01-25 SI SI200230630T patent/SI1413331T1/en unknown
- 2002-01-25 ES ES04000161T patent/ES2290562T3/en not_active Expired - Lifetime
- 2002-01-25 AR ARP020100269A patent/AR033855A1/en not_active Application Discontinuation
- 2002-01-25 RS RSP-2010/0015A patent/RS20100015A/en unknown
- 2002-01-25 DK DK04000161T patent/DK1413331T3/en active
- 2002-01-25 CZ CZ20032030A patent/CZ301871B6/en not_active IP Right Cessation
- 2002-01-25 DE DE60216890T patent/DE60216890T2/en not_active Expired - Lifetime
- 2002-01-25 ES ES02714773T patent/ES2274013T3/en not_active Expired - Lifetime
- 2002-01-25 CN CNB028072081A patent/CN100509058C/en not_active Expired - Lifetime
- 2002-01-25 EP EP04000161A patent/EP1413331B1/en not_active Expired - Lifetime
- 2002-01-25 CZ CZ2010307A patent/CZ309209B6/en not_active IP Right Cessation
- 2002-01-25 SK SK948-2003A patent/SK287988B6/en not_active IP Right Cessation
- 2002-01-25 NZ NZ525921A patent/NZ525921A/en not_active IP Right Cessation
- 2002-01-25 DE DE60222773T patent/DE60222773T2/en not_active Expired - Lifetime
- 2002-01-25 IL IL15644502A patent/IL156445A0/en unknown
- 2002-01-25 EP EP02714773A patent/EP1353696B1/en not_active Expired - Lifetime
- 2002-01-25 MX MXPA03006725A patent/MXPA03006725A/en active IP Right Grant
- 2002-01-25 RS YUP-586/03A patent/RS51449B/en unknown
- 2002-01-25 SK SK50001-2012A patent/SK288217B6/en not_active IP Right Cessation
- 2002-01-25 HU HU1500186A patent/HU230253B1/en unknown
- 2002-01-25 KR KR1020037009749A patent/KR100596257B1/en active IP Right Review Request
- 2002-01-25 ME MEP-278/08A patent/MEP27808A/en unknown
- 2002-01-25 RU RU2003126184/15A patent/RU2356550C2/en active
- 2002-01-25 HU HU0303915A patent/HUP0303915A3/en not_active Application Discontinuation
- 2002-05-01 US US10/136,968 patent/US7030106B2/en not_active Expired - Lifetime
-
2003
- 2003-06-15 IL IL156445A patent/IL156445A/en unknown
- 2003-07-23 ZA ZA2003/05693A patent/ZA200305693B/en unknown
- 2003-07-25 NO NO20033355A patent/NO331512B1/en not_active IP Right Cessation
- 2003-12-18 HK HK03109220A patent/HK1056696A1/en not_active IP Right Cessation
- 2003-12-18 HK HK04106306A patent/HK1063607A1/en not_active IP Right Cessation
-
2004
- 2004-05-20 CL CL200401174A patent/CL2004001174A1/en unknown
- 2004-11-29 US US10/998,400 patent/US7612058B2/en active Active
-
2005
- 2005-06-22 US US11/158,429 patent/US20060199793A1/en not_active Abandoned
-
2007
- 2007-02-20 CY CY20071100238T patent/CY1108000T1/en unknown
- 2007-05-28 JP JP2007141163A patent/JP4937836B2/en not_active Expired - Lifetime
- 2007-08-29 US US11/897,227 patent/US20080058306A1/en not_active Abandoned
- 2007-11-12 JP JP2007293724A patent/JP2008088184A/en active Pending
- 2007-11-28 AR ARP070105283A patent/AR064012A2/en unknown
- 2007-12-03 CY CY20071101535T patent/CY1107045T1/en unknown
-
2008
- 2008-05-13 IL IL191417A patent/IL191417A/en active IP Right Grant
-
2011
- 2011-02-09 EC EC2011004702A patent/ECSP11004702A/en unknown
-
2012
- 2012-01-31 JP JP2012018544A patent/JP2012087149A/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1999008501A2 (en) * | 1998-04-23 | 1999-02-25 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
WO2002026729A2 (en) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
WO2002050068A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
WO2002050027A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
WO2002050060A1 (en) * | 2000-12-21 | 2002-06-27 | Avantis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
WO2002064094A2 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
Non-Patent Citations (4)
Title |
---|
"Study showed ezetimibe significantly reduced levels fo LDL cholesterol or "bad" cholesterol in patients", SCHERING PRESS RELEASE, 21 May 2001 (2001-05-21), pages 1 - 3, XP002224764, Retrieved from the Internet <URL:http://www.sch-plough.com/news/2001/research/20010521.html> [retrieved on 20021211] * |
DAVIS HARRY R JR ET AL: "The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 50, no. 10, October 2001 (2001-10-01), pages 1234 - 1241, XP008011711, ISSN: 0026-0495 * |
KOSOGLOU T. ET AL: "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions", ATHEROSCLEROSIS, vol. 2, no. Suppl, 2001, pages 89, XP001132089 * |
KOSOGLOU T. ET AL: "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe", ATHEROSCLEROSIS, vol. 2, no. Suppl, 2001, pages 38, XP001132091 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002058732A3 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2002058731A3 (en) | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | |
WO2005046797A3 (en) | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | |
WO2002058733A3 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2002058734A3 (en) | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | |
WO2002058685A3 (en) | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
MXPA05009501A (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia. | |
EP1507529B8 (en) | Combination comprising valsartan, amlodipine and hydrochlorothiazide | |
WO2002098350A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
WO2003026643A3 (en) | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors | |
WO2001087343A3 (en) | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor | |
AU2003263760A1 (en) | Methods for the treatment or prevention of obesity | |
MXPA05009502A (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia. | |
WO2004019874A3 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
EP1864680A3 (en) | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2002085302A3 (en) | Methods of treating intestinal inflammation | |
WO2003101379A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
EP1859796A3 (en) | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors | |
ECSP034702A (en) | COMBINATIONS DEACTIVATOR (S) OF THE RECEIVER OF PEROXISMAL PROLIFERATION ACTIVATION (PPAR) AND INHIBITOR (ES) OF STEROL ABSORPTION AND TREATMENT FOR VASCULAR INDICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-586/03 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 525921 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 156445 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-500567 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434682 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002714773 Country of ref document: EP Ref document number: 2002247019 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/05693 Country of ref document: ZA Ref document number: 1020037009749 Country of ref document: KR Ref document number: 200305693 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9482003 Country of ref document: SK Ref document number: PV2003-2030 Country of ref document: CZ Ref document number: 2002559066 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/006725 Country of ref document: MX Ref document number: 1153/CHENP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 03064030A Country of ref document: CO Ref document number: 03064030 Country of ref document: CO |
|
B | Later publication of amended claims |
Free format text: 20030515 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028072081 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002714773 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2030 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009749 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 525921 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525921 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020037009749 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002714773 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191417 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2010-307 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref country code: SK Ref document number: SK A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201507567 Country of ref document: ID |